Survival differences in childhood and young adult acute myeloid leukemia: A cross-national study using US and England data

Publication date: June 2018

Source: Cancer Epidemiology, Volume 54

Author(s): Sherlly Xie, Md Jobayer Hossain

Abstract

Background

Acute myeloid leukemia (AML) is a serious disease with complex etiology and marked variation in survival. Known prognostic factors include AML subtypes, age at diagnosis and sex. However, survival outcomes may vary across healthcare systems. In this study, we evaluated the survival patterns in individuals diagnosed with AML at ages 0–24 years in the US and England between prognostic features and across countries.

Methods

We obtained data on 4387 and 2194 subjects from the US Surveillance Epidemiology and End Result registries and UK National Cancer Data Repository. Subjects were diagnosed and followed in 1995–2014. Kaplan-Meier curve and stratified Cox proportional hazards regression were used in the analysis.

Results

Overall risk of mortality was 23% lower in English patients compared to that in the US patients (adjusted hazard ratio (aHR), 95% confidence Interval (CI): 0.77, 0.71–0.84). Survival difference of similar extent was observed in subgroups of sex and age at diagnosis. However, mortality risks between two countries varied substantially across AML subtypes, especially in AML inv(16) (1.81, 0.61–5.34), AML with minimal differentiation (0.54, 0.25–1.17), AML without maturation (0.38, 0.20–0.74) and AML with maturation (0.52, 0.31–0.86).

Conclusions

Similar to the population trend, mortality risk across sex, age at diagnosis, and most AML subtypes was lower in England. Survival outcome for AML with and without maturation in England was better than the population trend, while that for AML inv(16) was worse. Our findings suggest that future etiologic and policy research may uncover the underlying mechanisms and contribute to closing these morality gaps.

https://ift.tt/2lX1g8k